NATURAL KILLER CELLS

Taking on SARS-CoV-2

A new study sheds light on how SARS-CoV-2 influences the way natural killer cells can recognize and kill infected cells.

PAOLA KUČAN BRLIĆ AND ILIJA BRIZIĆ

Responding to a viral infection is a complex, multistep process that involves a multitude of immune actors. Innate immunity acts first, deploying a battery of cellular and molecular entities which are not specific to the invading pathogen. Natural killer cells, for instance, are powerful antiviral agents which can recognize and kill cells infected with a broad range of viruses (Björkström et al., 2022). An adaptive immune response is then mounted, which specifically targets the virus causing the infection. For example, antibodies precisely selected to bind to a range of viral proteins are produced and released in large numbers. In the case of SARS-CoV-2, the virus that causes COVID-19, both innate and adaptive responses are considered to be essential for the control of infection (Merad et al., 2022).

For natural killer cells to eliminate their targets, a number of stress-induced molecules must first be displayed on the surface of infected cells; there, they can be recognized by receptors on natural killer cells, a process which activates the cells’ killing programme. However, some natural killer cells also recognize infected cells by harnessing virus-specific antibodies produced by the adaptive immune response. This mechanism, known as antibody-dependent cellular cytotoxicity (ADCC), involves natural killer cells expressing an activating receptor which interacts with the tail end of antibodies.

Despite the efficiency of natural killer cells, viruses often have a broad arsenal of strategies at their disposal to escape these cells. Whether SARS-CoV-2 actively evades early natural killer cell response, and whether antibodies engage these cells via ADCC to protect against COVID-19, remains unclear. Now, in eLife, Richard Stanton and colleagues at various institutions in the United Kingdom – including Ceri Fielding of Cardiff University as first author – report results showing how SARS-CoV-2 interferes with the recognition processes of natural killer cells during the early stages of infection (Fielding et al., 2022).

First, the team screened which proteins are expressed on the surface of infected cells. This showed that SARS-CoV-2 actively evades natural killer cells by harnessing virus-specific antibodies produced by the adaptive immune response. This mechanism, known as antibody-dependent cellular cytotoxicity (ADCC), involves natural killer cells expressing an activating receptor which interacts with the tail end of antibodies.

Related research article
Fielding CA, Sabberwal P, Williamson JC, Greenwood EJD, Crozier TWM, Zelek W, Seow J, Graham C, Huettner I, Edgeworth JD, Price DA, Morgan BP, Ladell K, Eberl M, Humphreys IR, Merrick B, Doores K, Wilson SJ, Lehner P, Wang EYC, Stanton RJ. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11:e74489. doi: 10.7554/eLife.74489
Interestingly, however, recent evidence suggests that the related viral protein Nsp13 can actually increase the activation of natural killer cells by interfering with a receptor which inhibits the cells’ killing response (Hammer et al., 2022). How these opposing effects of SARS-CoV-2 affect the way natural killer cells control infections in vivo remains to be determined.

Fielding et al. then showed that natural killer cells can be efficiently triggered by antibodies bound to SARS-CoV-2-infected cells (Figure 1B), demonstrating that the ADCC mechanism can activate these cells during COVID-19 infection. However, the antibodies triggering ADCC were not the ones targeting the spike protein, the viral component used in many current vaccines. In fact, further experiments revealed that vaccination-induced antibodies targeting the spike protein poorly engaged natural killer cells, a result in line with a study showing that vaccination-induced antibodies are not as good at mediating ADCC compared to infection-induced antibodies (Rieke et al., 2022). Fielding et al. then went on to reveal that the antibodies involved in ADCC were those produced in reaction to other viral proteins expressed at the surface of infected cells. In most COVID-19 patients, the infection-induced antibodies able to trigger ADCC persisted for at least six months.

Together, these results suggest that it could be possible to improve vaccine design by adding viral proteins which induce antibodies capable of triggering ADCC in natural killer cells to the current formulation. In addition, promoting natural killer cell activity by boosting ADCC response in patients with severe COVID-19 could become a therapeutic option, as these individuals show high levels of antibodies and impaired natural killer cell function (Merad et al., 2022; Witkowski et al., 2021).

Paola Kučan Brlić is in the Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
http://orcid.org/0000-0002-9178-9128
Ilija Brizić is in the Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
ilija.brizic@medri.uniri.hr
http://orcid.org/0000-0001-8839-7839

Competing interests: The authors declare that no competing interests exist.

Published 28 June 2022

References
Björkström NK, Strunz B, Ljunggren HG. 2022. Natural killer cells in antiviral immunity. Nature Reviews Immunology 22:112–123. DOI: https://doi.org/10.1038/s41577-021-00558-3, PMID: 34117484
Fielding CA, Sabberwal P, Williamson JC, Greenwood EJD, Crozier TWM, Zelek W, Seow J, Graham C, Huettenr I, Edgeworth JD, Price DA, Morgan BP, Ladell K, Eberl M, Humphreys IR, Merrick B, Doores K, Wilson SJ, Lehner PJ, Wang ECY, et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11:e74489. DOI: https://doi.org/10.7554/eLife.74489, PMID: 35587364
Hammer Q, Dunst J, Christ W, Picarazzi F, Wendorff M, Momayyezi P, Huhn O, Netskar HK, Maleki KT, Garcia M, Sekine T, Sohlberg E, Azzimato V, Aouadi M, Degenhardt F, Franke A, Spallotta F, Mørø M, Michælsson J, Björkström NK, et al. 2022. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells. *Cell Reports* **38**:110503. [DOI: https://doi.org/10.1016/j.celrep.2022.110503, PMID: 35235832]

Hsu JCC, Laurent-Rolle M, Pawlak JB, Wilen CB, Cresswell P. 2021. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. *PNAS* **118**:24. [DOI: https://doi.org/10.1073/pnas.2101161118, PMID: 34045361]

Merad M, Blish CA, Sallusto F, Iwasaki A. 2022. The immunology and immunopathology of COVID-19. *Science* **375**:1122–1127. [DOI: https://doi.org/10.1126/science.abm8108, PMID: 35271343]

Rieke GJ, van Bremen K, Bischoff J, ToVinh M, Monin MB, Schlabe S, Raabe J, Kaiser KM, Finnemann C, Odainic A, Kudaliyanage A, Latz E, Strassburg CP, Boesecke C, Schmidt SV, Krämer B, Rockstroh JK, Nattermann J. 2022. Natural killer cell-mediated antibody-dependent cellular cytotoxicity against SARS-CoV-2 after natural infection is more potent than after vaccination. The *Journal of Infectious Diseases* **225**:1688–1693. [DOI: https://doi.org/10.1093/infdis/jiac060, PMID: 35329975]

Thoms M, Buschauer R, Ameismeier M, Koepeke L, Denk T, Hirschenberger M, Kratzat H, Hayn M, Mackens-Kiani T, Cheng J, Straub JH, Stürzel CM, Fröhlich T, Berninghausen O, Becker T, Kirchhoff F, Sparrer KMJ, Beckmann R. 2020. Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. *Science (New York, N.Y.)* **369**:1249–1255. [DOI: https://doi.org/10.1126/science.abc8665, PMID: 32680882]

Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, Frischbutter S, Angermair S, Hohnstein T, Mattiola I, Nawrath P, McEwen S, Zocche S, Viviano E, Heinz GA, Maurer M, Kölsch U, Chua RL, Aschman T, Meisel C, et al. 2021. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. *Nature* **600**:295–301. [DOI: https://doi.org/10.1038/s41586-021-04142-6, PMID: 34695836]